KeyBanc downgraded Inspire Medical (INSP) to Sector Weight from Overweight without a price target The firm says its previous share thesis is “impaired” with the magnitude of the company’s 2025 guidance revisions. Inspire’s near- to mid-term visibility “appears incrementally uncertain” due to several new and existing headwinds, the analyst tells investors in a research note. KeyBanc adds that the company now plans to increase direct-to-consumer spend at a rate above expected sales growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Reports Q2 2025 Financials
- Closing Bell Movers: Palantir hits record highs on beat and raise
- Inspire Medical Systems Reports Q2 2025 Financial Results
- Inspire Medical down 22% after reporting Q2 earnings, lowering FY25 guidance
- Inspire Medical reports Q2 adjusted EPS 45c, consensus 20c